Amsterdam Molecular Therapeutics (AMT) has reported an increase in operating loss to E9.9m for the six months ended June 30, 2009, from E9.1m for the same period in 2008. The net loss for the first half of 2009 was E9.4m, as compared to a net loss of E8.1m for the first half of 2008.
Sander van Deventer, CEO of AMT, said: AMT showed important results in the first half of 2009. We presented additional data showing the clinically important health benefit of our lead product, Glybera, while good progress was made in the further development of our pipeline-products and the strengthening of the company. The search process for a new permanent CEO is progressing expeditiously but carefully to ensure the engagement of a capable new CEO. All of this reinforces our position as a leader in gene therapy and gives us a strong foundation for further growth.
AMT also said that the key financial figures are well within the budgets for the first semester and therefore remain in line with the guidance that the company has given for 2009.